Illumina and IBM team up to create a standardized gene sequencing process to help in cancer research.
DNA sequencing firm, Illumina Inc., creates a spin-off company, GRAIL, to develop of what might be the world’s first accessible and universal blood tests to detect early signs of cancer.
According to Illumina Inc, the $1,000 human genome sequencer has debuted. The genome sequencer dubbed HiSeq X has been designed to process 20,000 genomes a year that will cost $1,000 each.
Using the genetic sequencing firm Illumina, the test will provide information about 97 genes that influence the risk of cancer.